Ten pharmaceutical giants join US research initiative

February 4, 2014

Government researchers will collaborate with 10 large pharmaceutical companies on a $230 million initiative to speed development of new medications for major diseases, the US National Institutes of Health announced Tuesday.

The five-year initiative targets Alzheimer's Disease, , and lupus, and may be expanded to other ailments, the NIH said.

The goal is to pool resources among NIH and the companies, normally vigorous competitors, to enable analysis of large data sets to track disease progression and the effect of therapies.

Data and early-stage research will be shared and made publicly available, and companies are expected to compete on developing commercial drugs once research passes the preliminary phase.

"Currently, we are investing a great deal of money and time in avenues with high failure rates, while patients and their families wait," said NIH Director Francis Collins.

The challenge "is beyond the scope of any one of us and it's time to work together in new ways to increase our collective odds of success," Collins said.

Taking a drug from early discovery through government approval takes over a decade and 95 percent fail the test. That takes the cost of one success to more than $1 billion, NIH said.

The initiative will be overseen by steering committees led by representatives of NIG and the Food and Drug Administraiton, the private sector companies and patient advocacy groups.

"Our most critical health challenges require new, innovative ways to develop medicines and vaccines," said Rupert Vessey, a at Merck, which is joining the initiative.

"Collaborations such as this, that exchange data, share insights and generate knowledge will be important to unravelling the mysteries of the diseases that cause suffering for individuals and a burden to our society."

The other participating companies are: AbbVie, Biogen, Bristol-Myers Squibb, Eli Lilly, GSK, Johnson & Johnson, Pfizer, Sanofi and Takeda.

Explore further: Research slows on mental health drugs as investment shrinks

Related Stories

Research slows on mental health drugs as investment shrinks

November 26, 2013
Research into medications to treat mental health disorders, which affect almost a quarter of the US population, has slowed as major pharmaceutical companies cut back investment in this area, psychiatrists say.

Deciphering the DNA of Alzheimer's patients

December 4, 2013
(HealthDay)—Data that details every gene in the DNA of 410 people with Alzheimer's disease can now be studied by researchers, the U.S. National Institutes of Health announced this week.

US approves diabetes drug with new approach (Update)

January 8, 2014
The U.S. Food and Drug Administration on Wednesday approved a new diabetes drug from Bristol-Myers Squibb and AstraZeneca that uses a novel approach to reduce blood sugar.

Sanofi sues Eli Lilly for patent infringement

January 31, 2014
French pharmaceutical giant Sanofi has said it is suing US rival Eli Lilly in an American court for infringing four patents relating to its diabetes treatments.

NIH and Lilly to generate public resource of approved and investigational medicines

March 13, 2012
The National Institutes of Health and Eli Lilly and Company will generate a publicly available resource to profile the effects of thousands of approved and investigational medicines in a variety of sophisticated disease-relevant ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.